Drug Trial Radar · NCT05126719
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
238
Planned (sponsor's estimate)
Start
Apr 6, 2023
Primary completion
Dec 30, 2024
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
MRG003Drug
Administered intravenously
Capecitabine tabletsDrug
Administered peros
Docetaxel injectionDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Baseline to disease progression, intolerable drug-related toxicities, withdrawal of consent, or study discontinuation for any reasons (up to 24 months)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Maoming People's Hospital
Maoming, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Yue Bei People's Hospital
Shaoguan, Guangdong, China
Zhongshan City People's Hospital
Zhongshan, Guangdong, China
Guigang City People's Hospital
Guigang, Guangxi, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Hainan General Hospital
Haikou, Hainan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
Ganzhou Cancer Hospital
Ganzhou, Jiangxi, China
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Yibin Second People's Hospital
Yibin, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.